EPISODE · Apr 25, 2025 · 28 MIN
Epicrispr Biotechnologies' CEO Amber Salzman describes how her company will be utilizing AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy
from BiotechTV - News · host BiotechTV
She describes why such an analysis would be beneficial in analyzing clinical benefit for this type of condition - where the patient population is heterogenous in how they are affected by the disease. Plus, a description of Epicrispr's epigenome approach to science, and her personal relationship to facioscapulohumeral muscular dystrophy.
Embed this episode
NOW PLAYING
Epicrispr Biotechnologies' CEO Amber Salzman describes how her company will be utilizing AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.